Bluechiip Limited Stock Market Press Releases and Company Profile
Share Purchase Plan (SPP) Offer Documents
Share Purchase Plan (SPP) Offer Documents

Melbourne, Oct 30, 2019 AEST (ABN Newswire) - Bluechiip Ltd (googlechartASX:BCT) is offering Eligible Shareholders the opportunity to participate in the Bluechiip Share Purchase Plan (SPP).

The launch of the SPP follows the recent announcement by Bluechiip of a $4.6 million equity placement. Bluechiip is committed to ensuring its loyal shareholders also have the opportunity to acquire shares at the same price as participants in the placement.

Pursuant to the SPP, Eligible Shareholders may apply to purchase up to A$30,000 worth of new fully paid ordinary shares in Bluechiip (New Shares) (subject to any scale back) at an issue price of 15 cents per New Share (Issue Price) without paying brokerage or other transaction costs. The Issue Price is the same price paid by investors in the placement announced to ASX on 24 October 2019 and represents a discount of 6.4% to the volume weighted average price of fully paid ordinary shares (Shares), calculated over the last 15 days on which sales of Shares were recorded on ASX before the day on which the SPP was announced.

To view the Share Purchase Plan, please visit:
https://abnnewswire.net/lnk/X0VSTKE7


About Bluechiip Limited

Bluechiip Ltd ASX BCTBluechiip Ltd (ASX:BCT) understands that every sample - stem cells, blood, eggs, sperm and other biospecimens - is critical, so our objective is to manage each one with optimal quality in the most efficient way. Bluechiip's advanced management solution is the only one that provides sample temperature with ID in cryogenic environments to. Most importantly, this delivers confidence in every sample.

Bluechiip's unique patented technology is a MEMS-based wireless tracking solution that contains no electronics. It represents a generational change from current tracking methods such as labels (hand-written and pre-printed), barcodes (linear and 2D), and Radio Frequency Identification. Bluechiip tags are either embedded or manufactured into storage products such as vials or bags. Each product can be easily identified, and critical information such as sample temperature, is detected by readers and stored in the Bluechiip software. In addition to functioning in extreme temperatures, the Bluechiip(R) Advanced Sample management solution can survive autoclaving, gamma irradiation sterilization, humidification, centrifuging, cryogenic storage and frosting.

Bluechiip's technology has applications in healthcare, including in cryogenic storage facilities (biobanks and biorepositories), pathology, clinical trials and forensics. Other key markets include cold-chain logistics/supply chain, security/defence, industrial/manufacturing and aerospace/aviation.

Bluechiip: Delivering confidence in every sample.

 

https://twitter.com/bluechiip https://www.youtube.com/channel/UCaVcyO4O2oJ_9fLdMs6JIyQ https://www.linkedin.com/company/bluechiip-limited abnnewswire.com 


Contact

Corporate enquiries
Andrew McLellan
Managing Director - CEO
Ph: +61-457-823-470
andrew.mclellan@bluechiip.com

Media
Richard Allen
Ph: +61-3-9915-6341
Oxygen Financial PR
richard@oxygenpr.com.au



ABN Newswire
ABN Newswire This Page Viewed:  (Last 7 Days: 7) (Last 30 Days: 28) (Since Published: 2774)